crohn's disease

SEW 2871 is an orally available, highly selective S1P1 agonist with an EC50 of 13.8 nM.It reduces the number of lymphocytes in the blood and is used in studies related to diabetes, Alzheimer's disease, liver fibrosis, and inflammation. It activates ERK, Akt and Rac signaling pathways and induces S1P1 internalization and recycling.

Palmatine chloride an isoquinoline alkaloid, is an important medicinal herbal extract with diverse pharmacological and biological properties.

Oxazolone is a haptenating agent that can induce models of acute or chronic colitis and atopic dermatitis. It activates Th1/Th2 responses, leading to weight loss and diarrhea, and the resulting inflammation can be alleviated by anti-IL-4 antibodies, anti-TNF-α antibodies, or IL-13R2α-Fc fusion proteins. It is also suitable for studying gene expression related to inflammatory bowel disease in zebrafish.

Etiprednol dicloacetate (BNP-166) is a corticosteroid with anti-inflammatory activity.Etiprednol dicloacetate inhibits the accumulation of eosinophils and can be used in the study of inflammatory airway diseases such as asthma and in the treatment of Crohn's disease.

5-Acetylsalicylic acid (5-acetyl-2-hydroxybenzoic acid) has anti-inflammatory effects and can be used to treat inflammatory bowel disease, including ulcerative colitis, inflamed anus or rectum, and to maintain remission in Crohn's disease.

1. Palmatine (Burasaine) is an inhibitor of dopamine generation. 2. Palmatine could potentially be developed for the treatment of flavivirus infections. 3. Palmatine has been used in the treatment of jaundice, dysentery, hypertension, inflammation, and liver-related diseases.

TNF-α-IN-24 (Example 15) is a TNF-α inhibitor with an IC50 value of 4.1 nM. It is applicable in research on inflammatory and autoimmune diseases such as rheumatoid arthritis and Crohn's disease.

Cholic acid-Glu is a derivative of Cholic acid. Its abundance rises in Crohn's disease. This compound can enhance the activation of PXR in intestinal organoid tissues and significantly increase the expression of the downstream PXR target gene, Cyp3a11.

Keap1-IN-2 (Compound 164) is an inhibitor of KEAP1 with an IC50 of 2 nM. It indirectly activates Nrf2 by blocking KEAP1, thereby enhancing cellular antioxidant capacity. By preventing KEAP1-mediated degradation of Nrf2, Keap1-IN-2 promotes the accumulation and nuclear translocation of Nrf2. This compound is used in research on diseases related to oxidative stress, such as inflammatory bowel disease, Crohn's disease, and ulcerative colitis, which are immune-related conditions.

HW201877 is a potent, orally active inhibitor of 15-prostaglandin dehydrogenase (15-PGDH), with an IC50 value of 3.6 nM. It significantly increases PEG2 levels in A549 cells and demonstrates notable efficacy in animal models of tissue injury and fibrosis. HW201877 is utilized in research for inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF), and Crohn's disease (CD).

p38 MAPK-IN-10 (Compound 4) is an orally active and potent inhibitor of p38 MAP kinase, with an IC50 of 570 nM. It shows promise for research into chronic inflammatory diseases, including rheumatoid arthritis and Crohn's disease.

JAK1-IN-18 (Example 2) is a selective JAK1 inhibitor with an IC50 value of 0.15 nM, demonstrating significantly greater inhibitory potency for JAK1 compared to JAK2 and JAK3. It significantly reduces inflammation in ulcerative colitis (UC) mouse models induced by DSS and Crohn's disease (CD) rat models induced by DNBS. JAK1-IN-18 is applicable for research into autoimmune diseases (such as inflammatory bowel disease), viral infections (such as hepatitis B virus infection), and cancers (such as hematologic malignancies).

Loperamide oxide (R 58425) is a secreted antidiarrheal agent that increases peristalsis and inhibits intestinal absorption of water and ions and is used in the study of chronic diarrhea in patients with Crohn's disease.

Delmitide, a TNF-alpha production inhibitor, is used potentially for the treatment of Crohn's disease and ulcerative colitis.

CP-461 (OSI-461) is a pde2a / 5A inhibitor, which may be used in the treatment of renal cell carcinoma, prostate cancer, and Crohn's disease.

Semapimod tetrahydrochloride (CPSI-2364 tetrahydrochloride) is a synthetic ornithine mitogen-activated protein kinase blocker and pro-inflammatory cytokine production inhibitor that interferes with macrophage and microglia function. Sematimod tetrahydrochloride inhibits TLR4 signaling, TNF-α, IL-1β, and IL-6, and is used in the study of Crohn's disease and other inflammatory conditions.

Cosyntropin (acetate) stimulates the release of corticosteroids such as cortisol from the adrenal gland.

Sibofimloc (Antibiotic-202), an antibiotic compound, is used in treating bacterial infections.

Filgotinib (maleate) is a selective, orally active JAK1 inhibitor that effectively inhibits the activity of JAK1 (IC50: 10 nM), JAK2 (IC50: 28 nM), JAK3 (IC50: 810 nM) and TYK2 (IC50: 116 nM). maleate) can be used to study rheumatoid arthritis (RA) and Crohn's disease.

Omilancor (BT-11) is a direct LANCL2 (Lanthionine Synthetase Cyclase-Like 2) activator with oral activity for the treatment of Crohn's Disease (CD), Inflammatory Bowel Disease (IBD) and Ulcerative Colitis (UC).

Ozanimod (RPC-1063) (RPC1063) is a specific oral S1P Receptor 1 modulator. Ozanimod has been used in trials studying the treatment of Crohn's Disease, Ulcerative Colitis, Multiple Sclerosis, and Relapsing Multiple Sclerosis.

Filgotinib hydrochloride hydrate is a potent and selective JAK1 inhibitor under investigation for the treatment of rheumatoid arthritis (RA) and Crohn's disease.

Glepaglutide (ZP1848), a long-acting glucagon-like peptide-2 (GLP-2) analogue, functions as a potent GLP-2 receptor (GLP-2R) agonist, effectively reducing fecal output and enhancing intestinal absorption while alleviating small intestine inflammation. It holds potential for researching inflammatory bowel disease (IBD) and Crohn's disease [1] [2] [3].

Glepaglutide (ZP1848) acetate is a long-acting glucagon-like peptide-2 (GLP-2) analogue and a potent GLP-2 receptor (GLP-2R) agonist. It significantly reduces fecal output and enhances intestinal absorption while also mitigating inflammation in the small intestine. Glepaglutide acetate is relevant in researching inflammatory bowel disease (IBD) and Crohn's disease [1] [2] [3].